[1] Williams, C.H. (2015) Malignant Hyperthermia: Organon 9426 Was Evaluated in 10 MHS Pigs and 8 Control Pigs. Presented at EB2015 Boston, 1 April 2015, as FASEBJ 29: Abstract W109, #1039.1.
[2] Muir, A.W., Houston, J., Green, K.L., Marshall, R.J., Bowman, W.E. and Marshall, I.G. (1989) Effects of a New Neuromuscular Blocking Agent ORG-9426 in Anesthetized Cats and Pigs and in Isolated Nerve-Muscle Preparation. Brit J Physiol, 63, 400-410.
[3] Mamabe, N., Nitta, S., Nagashima, H., Duncalf, D. and Foldes F.F. (1989) The in-Vivo Neuromuscular Effects of ORG-9426 in Rats and Guinea-Pigs. Anesthesiology, 71, A774.
[4] Nagashima, H., Nguyen, H.D., Kinsey, A, Rosa, M., Hollinger, I., Goldiner, P.L. and Foldes, F.F. (1989) The Human Dose Response of ORG-9426. Anesthesiology, 71, A773.
[5] Foldes, F.F., Chaudry, I., Goldiner, P.L. and Nagashima, H. (1989) The in-Vitro Neuromuscular Effects of ORG-9426 in Rodents. Anesthesiology, 71, A772.
[6] Khuenl-Brady, K.S., Canfel, P.C., Miller, R.D., Castagnoli, K.P. and Agoston, S. (1989) Pharmacokinetics and Disposition of ORG-9616 and ORG-9426 in the Cat. Brit J Anaesth, 62, 225P-226P.
[7] Buzello, W., Williams, C.H., Chandra, P., Watkins, M.L. and Dozier, S.E. (1985) Vecuronium and Porcine Malignant Hyperthermia. Anesthesia and Analgesia, 64, 515-519.
http://dx.doi.org/10.1213/00000539-198505000-00012
[8] Hoech Jr., G.P., Roberts, J.T., Williams, C.H., Waldman, S.D., Simpson, S.T., Trim, C.M. and Brazile, J. (1980) Prevention of Porcine Malignant Hyperthermia with Metocurine. In: Thermoregulatory Mechanisms and Their Therapeutic Implications, 4th International Symposium on the Pharmacology of Thermoregulation, Oxford1979, Karger, Basel, 137-141.
[9] Williams, C.H., Dozier, S.E., Ilias, W.K. and Fulfer, R.T. (1984) Porcine Malignant Hyperthermia: Testing of Atracurium in MH Susceptible Pigs. Manuscript.
[10] Buzello, W., Williams, C.H., Chandra, P. and Watkins, M.L. (1984) Preliminary Studies on the Response of Malignant Hyperthermia Pigs to Vecuronium. Intl. Anesth. Research Soc. 58th Congress Abstracts, 67.
[11] Williams, C.H., Farias, M., Marvasti, M.A, Knight, A.B., Ekery, D.O., Daly, I.W. and Zayed, I. (1990) Malignant Hyperthermia Induction in Susceptible Swine Following Exposure to Arduan. IntI Anesth Research Soc 64th Congress, Honolulu, 10-14 March 1990.
[12] Williams, C.H., Dozier, S.E., Ilias, W.K. and Fulfer, R.T. (1985) Porcine Malignant Hyperthermia: Testing of Atracurium in MH Susceptible Pigs. Anesthesia and Analgesia, 64, 112.
[13] Williams, C.H., Hoech, G.P. and Zukaitis, M.G. (2014) A Review of the Factors Affecting the Incidence of Malignant Hyperthermia in the Greater Kansas City Area. Advances in Bioscience and Biotechnology, 5, 452-461.
http://dx.doi.org/10.4236/abb.2014.55055
[14] Williams, C.H., Dozier, S.E., Ilias, W.K., Fulfer, R.T., Zukaitis, M.G. and Hoech, G.P. Diltiazem and Malignant Hyperthermia. Submitted to Anesthesia and Analgesia.
[15] Williams, C.H., Dozier, S.E. and Shanklin, M.D. (1986) Metabolic Rate in Malignant Hyperthermia Susceptible (MHS) Pigs. In: Tumbleson, M.E., Ed., Swine in Biomedical Research, Plenum, New York, 573-584.
[16] Williams, C.H. (2014) Malignant Hyperthermia: A Runaway Thermogenic Futile Cycle at the Sodium Channel Level. Advances in Bioscience and Biotechnology, 5, 197-200.
http://dx.doi.org/10.4236/abb.2014.53025
[17] Williams, C.H. (2015) Malignant Hyperthermia: Organon 9426 Was Evaluated in 10 MHS Pigs and 8 Control Pigs. FASEB J, 29, 1.1039.1.